{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:46:13Z","timestamp":1790142373642,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.3816\/clm.2009.n.056","type":"journal-article","created":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T01:06:30Z","timestamp":1251939990000},"page":"278-288","source":"Crossref","is-referenced-by-count":135,"title":["Treatment of Multiple Myeloma: A Comprehensive Review"],"prefix":"10.3816","volume":"9","author":[{"given":"Robert A.","family":"Kyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.056_bib1","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota -Trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.n.056_bib2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0","article-title":"Cancer incidence and mortality, 1973-1995: a report card for the U.S.","volume":"82","author":"Wingo","year":"1998","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.n.056_bib3","series-title":"SEER cancer statistics review, 1975-2003","year":"2006"},{"key":"10.3816\/CLM.2009.n.056_bib4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.056_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4065\/81.5.693","article-title":"Monoclonal gammopathy of undetermined significance, Waldenstr\u00f6m macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment","volume":"81","author":"Rajkumar","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLM.2009.n.056_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.056_bib7","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLM.2009.n.056_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.leu.2404516","article-title":"A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.056_bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.056_bib11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.1997.2783095.x","article-title":"Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma","volume":"98","author":"Goldschmidt","year":"1997","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.056_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04107.x","article-title":"Mobilization of CD34+ cells in elderly patients (>\/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen","volume":"120","author":"Morris","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.056_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high dose therapy for multiple myeloma including the role of plerixafor [AMD 3100]","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.056_bib14","first-page":"447s","article-title":"Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A08): A trial coordinated by the Eastern Cooperative Oncology Group","volume":"25","author":"Rajkumar","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.056_bib15","first-page":"455s","article-title":"Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (ERA03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete-and overall-response rates in treatment-naive symptomatic multiple myeloma","volume":"111","author":"Niesvizky","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib17","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma [erratum appears in N Engl J Med 2000; 342:364]","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib18","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, doubleblind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib19","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2006-03-013086","article-title":"Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma","volume":"108","author":"Offidani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib20","doi-asserted-by":"crossref","first-page":"238a","DOI":"10.1182\/blood.V108.11.796.796","article-title":"Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma","volume":"108","author":"Jagannath","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib21","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib22","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics","volume":"25","author":"Rosinol","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib23","doi-asserted-by":"crossref","first-page":"30A","DOI":"10.1182\/blood.V110.11.73.73","article-title":"Bortezomib (Velcade(R))-Thalidomide-Dexamethasone (VTD) vs. Thalidomide-Dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)","volume":"110","author":"Cavo","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/bjc.1995.65","article-title":"VAD chemotherapy as remission induction for multiple myeloma","volume":"71","author":"Anderson","year":"1995","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2009.n.056_bib26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/bmt.2008.24","article-title":"Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT","volume":"41","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.n.056_bib27","article-title":"Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly-diagnosed multiple myeloma","volume":"112","author":"Cavo","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V110.11.450.450","article-title":"Velcade\/dexamethasone (Vel\/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): Updated results of the IFM 2005\/01 trial","volume":"110","author":"Harousseau","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib29","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2001.19.17.3771","article-title":"Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial","volume":"19","author":"Stewart","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3324\/haematol.10535","article-title":"Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study","volume":"92","author":"Bourhis","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.056_bib31","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib32","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib33","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib34","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma [erratum appears in N Engl J Med 2004; 350:2628]","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib35","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib36","first-page":"23","article-title":"Single versus tandem high dose therapy (HOT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ASBC: Results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM)","volume":"4","author":"Fermand","year":"2003","journal-title":"Hematology J"},{"key":"10.3816\/CLM.2009.n.056_bib37","article-title":"Prognostic factors at the time of single autotransplantation in 451 myeloma patients treated with 200 mg\/m2 Melphalan: Results equivalent to tandem autotransplantation","volume":"100","author":"Sirohi","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib38","article-title":"Long-term outcome of myeloma patients treated with an elective single autograft with follow-up (\u2265 5 years): Results comparable to tandem autotransplantation","volume":"100","author":"Sirohi","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib39","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib41","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib42","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2007-07-101212","article-title":"Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial","volume":"111","author":"Abdelkefi","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib43","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib44","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.056_bib45","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib46","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib47","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib48","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib49","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib50","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.n.056_bib51","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.n.056_bib52","doi-asserted-by":"crossref","first-page":"31a","DOI":"10.1182\/blood.V110.11.75.75","article-title":"Melphalan-Prednisone-Thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients \u2265 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01\/01","volume":"110","author":"Hulin","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib53","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2013Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.056_bib55","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLM.2009.n.056_bib56","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","article-title":"S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide","volume":"21","author":"Zeldis","year":"1999","journal-title":"Clin Ther"},{"key":"10.3816\/CLM.2009.n.056_bib58","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib59","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib60","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib61","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib62","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib63","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib64","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib65","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib66","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.056_bib67","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib68","first-page":"1","article-title":"The survival time of patients with plasmocytic myeloma","volume":"9","author":"Osgood","year":"1960","journal-title":"Cancer Chemother Rep"},{"key":"10.3816\/CLM.2009.n.056_bib69","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"[Clinical experiences with sarcolysin in neoplastic diseases.]","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"10.3816\/CLM.2009.n.056_bib70","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.056_bib72","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib73","first-page":"739","article-title":"Scintigraphic evaluation of the skeleton in multiple myeloma","volume":"55","author":"Wahner","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLM.2009.n.056_bib74","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib75","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib76","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","article-title":"Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw","volume":"14","author":"Raje","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.056_bib77","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/leu.2008.127","article-title":"The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement","volume":"22","author":"Hussein","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.056_bib78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update","volume":"26","author":"Rizzo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.056_bib79","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.056_bib80","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and management of multiple myeloma 2005","volume":"132","author":"Smith","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.056_bib81","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/088506669501000304","article-title":"Hyperviscosity syndrome","volume":"10","author":"Gertz","year":"1995","journal-title":"J Intensive Care Med"},{"key":"10.3816\/CLM.2009.n.056_bib82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.056_bib83","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.056_bib84","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:09:06Z","timestamp":1590106146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1557919011700038"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.056","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}